Evolva Acquires Resveratrol Programme From Fluxome
date:Dec 10, 2012
te in the next 12 months.

Applying IFRS standards, revenues in 2012 are expected to reach c. CHF 7 million, slightly lower than the earlier indicated range of CHF 8-10 million in 2012 (2011: CHF 11 million). Based on current partnering discussions, we expect revenues in 2013 to increase significantly relative to 2012.

We maintain our expectation of a net loss for 2012 at the same level as in 2011 (CHF 22.9 million) and a net cash outflow for 2012 of approximately CHF 13 million (2011: CHF 17.5
14/16 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/27 21:52